Concomitant Liver Biopsy During Bariatric Surgery: No Increase in Major Complications or Readmissions but Associated with Higher Transfusion Requirements - An Analysis of the MBSAQIP Database - Scorecard - MDSpire
Advertisement
Concomitant Liver Biopsy During Bariatric Surgery: No Increase in Major Complications or Readmissions but Associated with Higher Transfusion Requirements - An Analysis of the MBSAQIP Database
Clinical Scorecard: Liver Biopsy Performed Concurrently with Bariatric Surgery: No Significant Rise in Major Complications or Readmissions, but Increased Need for Transfusions - Insights from the MBSAQIP Database Analysis
MASLD progression linked to morbid obesity, insulin resistance, diabetes, dyslipidemia, and visceral adiposity; liver biopsy provides definitive diagnosis and staging
Target Population
Patients undergoing bariatric surgery, particularly those with morbid obesity at high risk for MASLD/MASH
Care Setting
Bariatric surgery centers accredited by MBSAQIP in the United States and Canada
Key Highlights
MASLD prevalence is 75–95% among bariatric surgery candidates, with 20–35% having advanced disease including steatohepatitis and fibrosis.
Intraoperative liver biopsy remains the gold standard for MASLD diagnosis and prognostication despite emerging non-invasive tools.
Concurrent liver biopsy during bariatric surgery does not significantly increase major complications or readmissions but is associated with higher transfusion requirements.
Guideline-Based Recommendations
Diagnosis
Liver biopsy is recommended intraoperatively during bariatric surgery to accurately diagnose and stage MASLD/MASH when non-invasive methods are insufficient.
Use of CPT codes 47000 and 47001 to identify liver biopsy procedures during surgery.
Management
Bariatric surgery is effective in managing morbid obesity and improving MASLD histology in eligible patients.
Consider intraoperative liver biopsy to guide postoperative management and surveillance for advanced fibrosis or cirrhosis.
Monitoring & Follow-up
Close postoperative monitoring for bleeding-related complications, especially transfusion needs, when liver biopsy is performed concurrently.
Utilize MBSAQIP data for quality improvement and outcome tracking in bariatric surgery patients undergoing liver biopsy.
Risks
Increased risk of bleeding and transfusion requirements associated with concurrent liver biopsy during bariatric surgery.
No significant increase in 30-day major complications or mortality observed with concomitant liver biopsy.
Patient & Prescribing Data
Morbidly obese patients undergoing bariatric surgery with or without concurrent liver biopsy
Concurrent liver biopsy is safe with respect to major complications but requires vigilance for bleeding; bariatric surgery improves metabolic and histologic outcomes in MASLD.
Clinical Best Practices
Perform thorough preoperative assessment including comorbidities and functional status to stratify risk before concurrent liver biopsy.
Use standardized MBSAQIP data collection protocols to monitor outcomes and complications.
Balance benefits of definitive MASLD diagnosis via biopsy against bleeding risks, informing patient consent and surgical planning.
Incorporate updated MASLD guidelines and evolving surgical techniques to optimize patient outcomes.
by Juan S. Barajas-Gamboa, Kayanne Khoury, Valentin Mocanu, Mélissa V. Wills, Thomas H. Shin, Gustavo Romero-Velez, Matthew Allemang, Andrew T. Strong, Salvador Navarrete, Ricard Corcelles, A. Daniel Guerron, John Rodriguez, Matthew Kroh, Jerry T. Dang
Patients with preoperative vitamin D deficiency had higher postoperative pain scores and opioid use after mastectomy, including more than triple the odds of moderate to severe pain within 24 hours of surgery.
